drugset / Trial / NCT01576718

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718

Phase 2 Completed 889 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp Spiromax) when administered twice daily in subjects 12 years of age and older with severe persistent asthma who are uncontrolled on high dose ICS therapy.

Timeline

Start
2012-04
Primary completion
2013-07
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 50 ug Inhaled
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject Fluticasone propionate Other / unclassified 200 ug Inhaled
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Fluticasone propionate Other / unclassified 400 ug Inhaled
Background Salbutamol Unknown 90 ug Inhaled

Indications